ArticleFrontiers in endocrinology2026
Interpretable machine learning model based on routine metabolic laboratory indices to identify advanced chronic kidney disease.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Early identification of advanced chronic kidney disease (CKD), a condition accompanied by profound metabolic and endocrine disturbances, is essential for timely nephrology referral and intervention. However, widely used risk equations often require albuminuria or repeated measurements that are not consistently available in routine clinical practice. Methods: We retrospectively analyzed adult patients from three different departments affiliated to one university, including two independent hospitals and a clinic department. Routinely collected demographic, clinical, and metabolic laboratory variables were used to develop machine learning models for distinguishing preserved kidney function (CKD G1-2) from advanced stages (G3a-5). Five algorithms were trained and internally validated in a development cohort, followed by external validation in an independent cohort. Model performance was assessed by discrimination, calibration, and interpretability using feature importance and SHAP (Shapley Additive Explanations). Results: Among 308 patients in the development cohort and 52 in the external cohort, the Gradient Boosting classifier achieved the best discrimination (AUC = 0.972 internally; 0.965 externally) with good calibration. Urea, kidney disease type, phosphorus, albumin, and lipid-related parameters-reflecting systemic metabolic dysregulation-emerged as key contributors to model predictions. Discussion: An interpretable Gradient Boosting model leveraging routinely measured metabolic laboratory data accurately identifies advanced CKD and captures clinically meaningful metabolic patterns associated with disease severity, supporting its potential integration into electronic health records for risk stratification and identification of advanced CKD among patients with established CKD in specialist care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.